Insider Transaction
On August 5, 2026, Roy Blunt, a director of Tenet Healthcare Corp (NASDAQ: THC), disposed of 600 shares of the company’s common stock. The shares were sold in multiple transactions at prices ranging from $262.52 to $262.70 per share, resulting in a weighted‑average sale price of $262.68. The total proceeds from the sale amounted to $157,608. Following the disposition, Mr. Blunt retained a direct holding of 4,589 Tenet Healthcare common shares.
Market Context
At the time of the sale, Tenet Healthcare’s shares were trading near their 52‑week high of $270.57 and had delivered a 56% total return over the preceding year. The stock was noted to be undervalued relative to its fair value, with a price‑to‑earnings multiple of 10.38.
Recent Operating Performance
Tenet Healthcare reported second‑quarter 2026 results that exceeded Wall Street expectations. Adjusted earnings were $6.12 per share, well above the consensus estimate of $4.23 per share. Revenue for the quarter was $5.63 billion, surpassing the forecast of $5.43 billion. In response to the strong performance, the company raised its full‑year outlook.
Analyst Reactions
Following the earnings release, several sell‑side analysts upgraded their price targets for Tenet Healthcare. Guggenheim increased its target to $283, citing the firm’s strategic focus on high‑acuity, non‑elective services. Raymond James lifted its target to $275, while UBS raised its target to $308, reflecting higher earnings expectations for 2026 and 2027. Cantor Fitzgerald also raised its target to $270, noting the company’s ability to exceed investor expectations despite changes in the Florida Directed Payment Program.